ClinicalTrials.gg
RecruitingNCT07244341Updated Oct 26, 2026

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase 1 interventional study of Valemetostat and Darolutamide in Metastatic Castration-resistant Prostate Cancer, sponsored by Daiichi Sankyo. Recruiting at 29 sites in 7 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 26, 2026First sites in Australia, France and Spain10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
1,256th of 3,023
60 · median 48
Started
2025
with 160 others
Phase 1
615 of 3,596
83 open now
Primary completion
2028-01
later than 611 of 971 live
Registered
3,449th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,256th largest by planned enrollment of the 3,023 interventional ones that give a count, is one of 161 that started in 2025, is one of 615 in phase 1, reaches primary completion later than 611 of the 971 other live ones, and was the 3,449th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Metastatic Castration Resistant Prostate Cancer
  • DS-3201
  • Valemetostat
  • Darolutamide
  • mCRPC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

The clinical site will screen for the full inclusion criteria per protocol.

  1. Adult males ≥18 years of age at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial participation is >18 years old).
  2. confirmed adenocarcinoma of the prostate. Cases exhibiting neuroendocrine differentiation are eligible for enrollment, except those with a diagnosis of pure small cell carcinoma, which is excluded.
  3. Evidence of disease progression as per the PCWG3 modified v1.1 criteria.
  4. Evidence of disease as confirmed by radiographic imaging (CT, MRI, or bone scan).
  5. Ongoing androgen deprivation at time of enrollment.

    • For participants currently being treated with luteinizing hormone-releasing hormone agonists or antagonists, therapy must have been initiated at least 4 weeks prior to enrollment and treatment must be continued throughout the trial.
  6. Baseline PSA expression level of ≥2 ng/mL, according to a documented testing result.
  7. Prior therapy with an Androgen Receptor Pathway Inhibitors (ARPI).
  8. PS of 0 or 1 assessed no more than 28 days prior to enrollment.
  9. Is willing and able to provide adequate fresh or with sufficient quantity and tissue quality. A mandatory newly obtained pretreatment biopsy is required, if not clinically and at an acceptable risk as determined by the investigator. If newly obtained tissue samples are not possible to obtain, archival tissue obtained from a lesion not previously irradiated and collected after the most recent prior therapy is acceptable.
  10. A male participant capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each trial intervention. The length of time required to continue after the last dose for each trial intervention is 3 months.

    • Must not freeze or donate sperm starting at screening and throughout the Treatment Period, and for at least 3 months after the final trial intervention administration.

Note: Preservation of sperm should be considered before enrollment in this trial.

  • Adhere to either of the following contraception methods:
  • True abstinence from penile-vaginal intercourse, when this is in line with the preferred and usual lifestyle of the participant, OR
  • Uses a penile/external condom when having penile-vaginal intercourse with an NPOCBP, PLUS partner use of an additional contraceptive method, as a condom may break or leak Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials. If the contraception requirements in the local label for any trial interventions are more stringent than those above, the local label requirements are to be followed.

Key Exclusion Criteria:

The clinical site will screen for the full exclusion criteria per protocol.

  1. Prior treatment with any epigenetic agents including but not limited to EZH1, EZH2, EZH1/2, or PRC2 inhibitors.
  2. Has a super scan as seen in the baseline bone scan. A super scan is defined as an intense symmetric activity in the bones and diminished renal parenchymal activity on baseline bone scan, such that the presence of additional metastases in the future could not be evaluated.
  3. Clinically active , spinal cord compression, or , defined as untreated or symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms.
  4. Uncontrolled or significant cardiovascular disease,
  5. Prior , active within the previous 3 years except for locally curable cancers that have been apparently cured or successfully resected, such as basal or squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the stomach, or carcinoma in situ of the breast.
  6. Has active or uncontrolled infection.
  7. Has active or uncontrolled infection.
  8. Has active or uncontrolled infection.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Part 1 (Dose Escalation)

    Participants will receive valemetostat at escalating doses in combination with darolutamide.

    Drug: Valemetostat · Drug: Darolutamide

  • Experimental
    Part 2 (Dose Expansion)

    Participants will receive valemetostat at 2 or more dose levels in combination with darolutamide.

    Drug: Valemetostat · Drug: Darolutamide

Interventions

  • Dose Escalation Part: Valemetostat will be administered at escalating doses. Dose Expansion Part: Valemetostat will be administered at 2 or more dose levels.

    Also known as: DS-3201

  • Dose Escalation Part: Darolutamide will be administered at a standard dose. Dose Expansion Part: Darolutamide will be administered at a standard dose.

    Also known as: NUBEQA

06

What researchers measure

Primary outcomes

  1. Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)

    A DLT is defined as any Treatment Emergent Adverse Event (TEAE) not attributable to disease or disease-related processes, environmental factors, unrelated trauma, etc, that occurs during the DLT evaluation period (Day 1 to Day 28) and is Grade ≥3.

    Time frame: Day 1 up to Day 28

  2. Part 1 and 2: Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE)

    TEAEs are defined as those Adverse Events (AEs) with start or worsening date during the on-treatment period (from the first dose date of trial intervention to 30 days after the last dose date of trial intervention).

    Time frame: From Screening up to approximately 5 years

Secondary outcomes

  1. Prostate-Specific Antigen (PSA) 50 Response Rate

    PSA50 response rate is defined as the percentage of participants who achieved a decline in PSA percent change from baseline by at least 50%, with a consecutive confirmation assessment at least 3 weeks later per the PCWG3 modified RECIST v1.1 criteria.

    Time frame: From Screening up to approximately 5 years

  2. Prostate-Specific Antigen (PSA) 90 Response Rate

    PSA90 response rate is defined as the percentage of participants who achieved a decline in PSA percent change from baseline by at least 90%, with a consecutive confirmation assessment at least 3 weeks later per the PCWG3 modified RECIST v1.1 criteria.

    Time frame: From Screening up to approximately 5 years

  3. Prostate-Specific Antigen (PSA) Nadir Response Rate

    PSA nadir response rate is defined as the proportion of participants who achieve a PSA level of ≤ 0.2 ng/mL at any time during the Treatment Period.

    Time frame: From Screening up to approximately 5 years

  4. Radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time (month) from the start date of trial intervention to the earlier date of the first objective documentation of radiographic disease progression as assessed by the investigator based on the PCWG3 modified RECIST v1.1 criteria or death due to any cause.

    Time frame: From Screening up to approximately 5 years

  5. Overall Survival (OS)

    OS is defined as the time (month) from the start date of trial intervention to the date of death due to any cause.

    Time frame: From Screening up to approximately 5 years

  6. Time to PSA Progression

    Time to PSA progression is defined as the time interval from the start date of trial intervention to PSA progression, per the PCWG3 modified RECIST v1.1 criteria. PSA progression is defined as: * A ≥25% increase and an absolute increase of ≥2 ng/mL from the nadir, confirmed by a second PSA measurement obtained at least 3 weeks later, in participants who experience a decline in PSA from baseline; OR * A ≥25% increase and an absolute increase of ≥2 ng/mL from baseline, occurring beyond 12 weeks from treatment initiation, in participants who do not experience a PSA decline from baseline.

    Time frame: From Screening up to approximately 5 years

  7. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants with measurable disease who achieved a BOR of confirmed CR or confirmed PR as assessed by the investigator according to the PCWG3 modified RECIST v1.1 criteria.

    Time frame: From Screening up to approximately 5 years

  8. Time to First SSRE (symptomatic bone fractures, spinal cord compression, surgery, or radiation to the bone, whichever is first)

    Time to first SSRE (symptomatic bone fractures, spinal cord compression, surgery, or radiation to the bone, whichever is first) is defined as the time interval from the start date of trial intervention to the date of the first observed SSRE.

    Time frame: From Screening up to approximately 5 years

  9. Total and Unbound Plasma Concentration of Valemetostat in Combination with Darolutamide

    Time frame: Cycle 1: Day 1, Day 8, Day 15. Cycles 2-5: Day 1 (Each cycle is 28 days)

07

Study locations

29 of 29 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jan 2028, 25 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 25 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartActual
Dec 3, 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Nov 30, 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added — first sites in Australia, France and Spain
Show 10 added (4 Australia, 4 Spain, 2 France)
  • Chris OBrien Lifehouse · Camperdown, Australia
  • Icon Cancer Centre Chermside · Chermside, Australia
  • Box Hill Hospital · Box Hill, Australia
  • Peter MacCallum Cancer Centre · Melbourne, Australia
  • Centre Oscar Lambret · Lille, France
  • Centre Leon Berard · Lyon, France
  • Hospital San Pedro · Logroño, Spain
  • Hospital Universitario Quironsalud Madrid · Pozuelo de Alarcón, Spain
  • Hospital Quironsalud Barcelona · Barcelona, Spain
  • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    10 sites added — first sites in Australia, France and Spain
    Show 10 added (4 Australia, 4 Spain, 2 France)
    • Chris OBrien Lifehouse · Camperdown, Australia
    • Icon Cancer Centre Chermside · Chermside, Australia
    • Box Hill Hospital · Box Hill, Australia
    • Peter MacCallum Cancer Centre · Melbourne, Australia
    • Centre Oscar Lambret · Lille, France
    • Centre Leon Berard · Lyon, France
    • Hospital San Pedro · Logroño, Spain
    • Hospital Universitario Quironsalud Madrid · Pozuelo de Alarcón, Spain
    • Hospital Quironsalud Barcelona · Barcelona, Spain
    • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07244341
Lead sponsor
Daiichi Sankyo
Collaborators
Bayer
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Dec 3, 2025
Primary completion
Jan 31, 2028 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Contact for Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valemetostat

Start the discussion